# Michael Shleifer

> Michael Shleifer is a Series A investor at SPRIM backing Biotechnology. See 4 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [SPRIM](https://shizune.co/investors/profile/sprim)
- Total investments: 4
- Last investment: May 2026
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/michael-shleifer-873b016a/

Michael Shleifer is a Series A investor at SPRIM focused on Biotechnology and Health Care. Dr. Michael Shleifer is the Founder and Managing Partner of SPRIM, as well as the Co-Founder of SPRIM Ventures.

## Contacts

5 contacts available for Michael Shleifer: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/michael-shleifer-4051?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Medical Device | 2 | 50% |
| Oncology | 1 | 25% |
| Biopharma | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Seed | 1 | 25% |
| Series D | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Australia | 2 | 50% |
| France | 1 | 25% |
| United States | 1 | 25% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NinaMED | NinaMED is a healthcare and medical solutions company associated with medical services and technology-enabled healthcare solutions. | $10M | Seed | May 13, 2026 |  |
| ErVimmune | ErVimmune creates novel immunotherapies that target non-conventional tumor antigens that are abnormally expressed in cancer cells and shared by tumors and patients, with a particular emphasis on meeting unmet medical requirements in cold malignancies. | $19.9M | Series A | Jan 21, 2026 |  |
| Vaxxas | Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $31.8M | Series D | Aug 25, 2025 |  |
| Doron Therapeutics | Doron Therapeutics is a clinical-stage biotechnology company that has developed intra-articular biologic drugs derived from placental tissue and consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective, and regenerative capabilities pivotal to the progressive and degenerative disease ofosteoarthritis. | $11M | Series A | Nov 25, 2024 |  |

4 of 4 investments shown.

## Co-investors
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 1 deal together
- [Crestone](https://shizune.co/investors/profile/crestone-dc1f) — VC Fund, 1 deal together
- [OneVentures](https://shizune.co/investors/profile/one-ventures) — VC Fund, 1 deal together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 1 deal together

## About SPRIM

VC Fund · Bengaluru, India

SPRIM is a management consulting company with a venture capital division, known as SPRIM Ventures.

5 contacts available at SPRIM.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Brenner | Chief Growth Officer | https://shizune.co/investors/profile/dan-brenner-2 |
| Ivan Jarry | Co-Founder & Managing Partner | https://shizune.co/investors/profile/ivan-jarry-b2b2 |
| Michael Shleifer | Managing Partner & Co-Founder | https://shizune.co/investors/profile/michael-shleifer-4051 |
| Olivier Shleifer | Co-Founder & Managing Partner | https://shizune.co/investors/profile/olivier-shleifer-8165 |
| Rodney Cheung | CIO | https://shizune.co/investors/profile/rodney-cheung |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Michael Shleifer invest in?

Michael Shleifer invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Michael Shleifer?

Public channels for Michael Shleifer include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Michael Shleifer last invest?

The most recent investment recorded for Michael Shleifer closed in May 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co